全文获取类型
收费全文 | 342篇 |
免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 7篇 |
妇产科学 | 28篇 |
基础医学 | 47篇 |
口腔科学 | 29篇 |
临床医学 | 77篇 |
内科学 | 29篇 |
皮肤病学 | 1篇 |
神经病学 | 32篇 |
特种医学 | 36篇 |
外科学 | 18篇 |
综合类 | 1篇 |
预防医学 | 23篇 |
眼科学 | 4篇 |
药学 | 12篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 9篇 |
2019年 | 12篇 |
2018年 | 8篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 20篇 |
2012年 | 12篇 |
2011年 | 12篇 |
2010年 | 11篇 |
2009年 | 10篇 |
2008年 | 24篇 |
2007年 | 16篇 |
2006年 | 18篇 |
2005年 | 15篇 |
2004年 | 11篇 |
2003年 | 9篇 |
2002年 | 8篇 |
2001年 | 7篇 |
2000年 | 10篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 8篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1980年 | 2篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1971年 | 3篇 |
1970年 | 7篇 |
1969年 | 4篇 |
1962年 | 1篇 |
排序方式: 共有356条查询结果,搜索用时 31 毫秒
1.
2.
I. O. Skalpe J. F. Bonneville P. Grane C. Gyldenstedt B. Otto D. T. Kristoffersen M. G. Svaland 《European radiology》1998,8(6):1054-1057
The purpose of this study was to evaluate and compare the radiographic efficacy and safety of iodixanol (Visipaque; 270 and
320 mg I/ml) and iohexol (Omnipaque; 300 mg I/ml) in myelography. The study was randomized, double-blind and comparative including
398 patients from five European university clinics. The radiographic visualisation was evaluated as poor, good or excellent.
Adverse events were recorded by interviewing the patients after the myelography, and each patient was given a questionnaire
to be returned after 1 week. In cervical myelography with cervical puncture more films with excellent quality was obtained
after iodixanol 320 mgI/ml compared with iohexol 300 mgI/ml (p = 0.009). Also in lumbar myelography iodixanol 320 mgI/ml compared favourably with iohexol 300 mgI/ml (p = 0.006). The most frequent adverse event was headache, which occurred in 5–35 % of patients during the first 24 h and in
19–61 % within the first 7 days, depending on the centre. There was no difference in frequency and severity of the adverse
effects between the contrast media.
Received 13 March 1997; Revision received 29 December 1997; Accepted 5 January 1997 相似文献
3.
Ingeborg S. Aaberge Philipp Oster Oddveig S. Helland Anne-Cathrine Kristoffersen Ellen Ypma E. Arne H?iby Berit Feiring Hanne N?kleby 《Clinical and Vaccine Immunology : CVI》2005,12(5):599-605
MenBvac and Menjugate are safe and efficacious vaccines. The purpose of this study was to evaluate safety and immunogenicity of the combination (MenB/C) of the lyophilized active components of the conjugated group C vaccine Menjugate when reconstituted with the full liquid group B outer membrane vesicle vaccine MenBvac compared to MenBvac and Menjugate given separately. At 6-week intervals, healthy adults were given one dose of MenB/C followed by two doses of MenBvac (MenB/C group), three doses of MenBvac (MenB group), or one dose of Menjugate and two doses of placebo (MenC group). Injection site reactions were frequent in all groups. However, most reactions were short lasting and mild or moderate in intensity, and the vaccines were found to be well tolerated, with no vaccine-related serious adverse events. MenB/C was immunogenic with regard to both serogroup B and C meningococci. Both the serum bactericidal assay and the enzyme-linked immunosorbent assay analyses showed that the immune responses of the combination vaccine were similar to the immune responses of its separate components MenBvac and Menjugate for both serogroup B and C. In conclusion, the combined MenB/C vaccine is safe and immunogenic. The two vaccines do not interact negatively with each other and can easily be administered in the same syringe. The induced immune responses suggest that the combined vaccine is likely to confer protection against systemic group B disease caused by the vaccine strain as well as against group C meningococcal disease. 相似文献
4.
Sidsel Ellingsen PhD Candidat. Cand. San. RN Åsa Roxberg PhD RN Kjell Kristoffersen PhD RN Jan Henrik Rosland MD PhD Herdis Alvsvåg RN 《Scandinavian journal of caring sciences》2014,28(3):458-468
The aim of this study is to describe the experience of time as it presents itself at the place being situated when living with severe incurable disease and receiving palliative care. The empirical data consist of 26 open‐ended interviews with 23 patients receiving palliative care at home, at a palliative day care, in a palliative bed unit in hospital or in a nursing home in Norway. A common meaning of a shifting space for living emerged from the analysis and was revealed through three different aspects: (i) Transition from a predictable to an unpredictable time: To live with severe incurable disease marks a transition to a changed life involving an ongoing weakened and altered body with bothersome symptoms making experience of time different and unpredictable. (ii) Transition between a safe and unsafe time: When time is unpredictable, feeling safe is revealed as essential to how time is experienced at the place being situated. (iii) To be in transition from a homely to a homeless existence: In a time of increased bodily weakness, unpredictable ailments and displacements, the sense of belonging to the place is revealed as significant to the experience of time. Not knowing where to be in a time of change is like an existential cry of distress where the foothold in existence is lost. The findings are discussed and interpreted as an embodied experience originating from the passage of time continually affecting life sometimes so fundamentally that it marks a transition to a changed space of life that is reflected in the experience of time. 相似文献
5.
6.
Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response 总被引:5,自引:0,他引:5
Omdal R Wildhagen K Hansen T Gunnarsson R Kristoffersen G 《Scandinavian journal of rheumatology》2005,34(3):229-232
Rituximab is a genetically engineered chimeric monoclonal immunoglobulin (Ig)G1 antibody. It binds the CD20 trans-membrane surface antigen expressed by mature B cells but not by antibody secreting plasma cells, and removes the cells by activating complement, inducing cell-mediated lysis, and by apoptosis. Mainly used for the treatment of non-Hodgkin's lymphomas, rituximab has recently been tried with favourable responses in rheumatoid arthritis, systemic lupus erythematosus, and other chronic immunological diseases. Wegener's granulomatosis (WG) is a granulomatous vasculitis with high morbidity and mortality. It is thought that anti-neutrophil cytoplasmatic antibodies (ANCA) with specificity for proteinase 3 (PR3) are possibly involved in the pathogenesis of the disease. Conventional therapy with cyclophosphamide and corticosteroids generally succeeds in inducing remission, but relapses frequently follow. Among the biological agents, tumour necrosis factor-alpha (TNF-alpha) inhibitors have been tried with some success. Based on a case report we recently treated three refractory WG patients with rituximab and achieved almost complete but temporary remission. CD20+ cells disappeared rapidly in peripheral blood, only to rise prior to subsequent disease flares occurring at 34, 63, and 54 weeks, respectively (Figure 1). A new flare occurred in one patient at 86 weeks. At the end of the observation periods (54, 102, and 120 weeks), only one patient had proteinuria. Chest radiographs became normal in two patients, while infiltrates remained unchanged in the third. Granulomatous retro-orbital or sinus masses in two patients seemed unresponsive to therapy. 相似文献
7.
Lena Ek Ove Almkvist Maria Kristoffersen Wiberg Giuseppe Stragliotto Anja Smits 《Neurocase》2013,19(6):503-511
We investigated the presence of cognitive impairment, in adults with presumed low-grade glioma at early stage of disease prior to major treatments, in relation to neurological symptoms and radiological characteristics of the tumour. Sixteen patients were evaluated. A subset of patients was identified with clearly impaired cognition. Patients with cognitive impairment often had large tumours in the left frontal lobe, were relatively young, and most of them were males. We conclude that cognitive dysfunction may be present already at early stage of disease, and that early identification of patients at risk is warranted. 相似文献
8.
9.
The purpose of this study is to identify central aspects of feelings in relation to the experience of being a brother or sister of someone who suffers from schizophrenia. The study makes use of a hermeneutical method for the collection of data as well as for the systemizing and interpretation of data. The participants in the study were 16 siblings of persons with diagnosed schizophrenia. In total 80 interviews were done, with an average length of 50 min. A theory of interrupted feelings was developed within the tension between empirical data and preunderstanding. Mixed feelings of grief, hope, anger, guilt and shame are interrupted by four interrelated factors: ambiguous loss, the fluctuating nature of the illness, an inner prohibition of feelings and the tendency of others to invalidate the feelings. The interruption may lead to a lonely and painful experience which is difficult both to process for oneself and to share with others. 相似文献
10.
Ulla Toft Lis Kristoffersen Steen Ladelund Lars Ovesen Cathrine Lau Charlotta Pisinger Lisa von Huth Smith Knut Borch-Johnsen Torben Jørgensen 《The international journal of behavioral nutrition and physical activity》2008,5(1):59